New fast-acting mealtime insulin, Fiasp®, now approved and available in Canada for the treatment of diabetes... Read More
Vancouver joins with global cities to push for action against urban diabetes Read More
Study finds Victoza® significantly reduced the risk of heart attack and stroke in people with type 2 diabetes. Read More
Press releases from the Denmark headquarters.
Visit the pressroom of the website for our headquarters in Denmark where you can access the latest corporate stock exchange announcements, an image library, interim and annual reports and other relevant communication from Novo Nordisk A/S.